EVITA Vitamin C Blood Cancer Trial
Analysis based on 6 articles · First reported Sep 21, 2026 · Last updated Sep 23, 2026
The results are an early-stage signal rather than proof, so they are unlikely to move broad markets or large pharmaceutical valuations in the near term. They could modestly support sentiment for vitamin and supplement makers and for companies pursuing blood cancer interception therapies, while reinforcing caution that phase 2 findings often fail in phase 3.
The phase 2 EVITA trial, a randomized, double-blind, placebo-controlled study, tested whether high-dose oral vitamin C (1000 mg/day for 12 months) could benefit patients with clonal cytopenia of undetermined significance or lower-risk myeloid malignancies, conditions that can progress to blood cancers such as leukemia. The trial enrolled 109 patients in Denmark and the United States, with 55 assigned to vitamin C and 54 to placebo. The primary endpoint, growth rate of precancerous or cancerous cells, showed no meaningful difference between groups. However, participants receiving vitamin C showed changes in inflammatory signaling consistent with better outcomes, and anemia, pneumonia, acute aseptic arthritis, and internal bleeding were less frequent, though gastrointestinal problems were more common. At a median follow-up of 33.6 months, 35 deaths occurred: 24 in the placebo group and 11 in the vitamin C group, according to an exploratory analysis that suggested better survival among those assigned vitamin C. Researchers, including Peter A. Jones of Van Andel Institute and Kirsten Green of Rigshospitalet, Copenhagen University Hospital, cautioned that the survival finding requires confirmation in a larger phase 3 trial and that it is too soon to recommend vitamin C for these patients. Results were published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society. The trial was led by the Van Andel Institute-Stand Up to Cancer Epigenetics Dream Team.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard